GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guardant Health GH · USD

Health Care · US listing · 🇺🇸 United States

Compare

158.79

+5.25%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$982.0m

FY2016FY2025

Net income

−$416.3m

FY2016FY2025

Free cash flow

−$233.1m

FY2016FY2025

Shareholders' equity

−$99.3m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$982.0m$739.0m$563.9m$449.5m$373.7m$286.7m$214.4m$90.6m$49.8m$25.2m
Research and development$364.2m$347.8m$367.2m$373.8m$263.2m$149.9m$86.3m$50.7m$25.6m$10.9m
Operating income−$437.2m−$443.6m−$564.7m−$544.4m−$411.0m−$254.9m−$82.4m−$92.9m−$82.7m−$43.8m
Net income−$416.3m−$436.4m−$479.4m−$654.6m−$405.7m−$253.8m−$75.7m−$85.1m−$83.2m−$46.1m
Diluted earnings per share-3.24-3.53-4.05-6.39-3.99-2.54-0.80-1.01-1.18-3.55

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$2.01bn$1.49bn$1.79bn$1.61bn$2.20bn$2.27bn$962.5m$587.4m$342.9m$116.6m
Cash and short-term investments$1.20bn$840.0m$1.17bn$1.01bn$932.7m$1.79bn$522.8m$419.0m$221.3m$95.3m
Total liabilities$2.11bn$1.63bn$1.63bn$1.55bn$1.56bn$916.2m$114.5m$62.5m$34.3m$36.9m
Debt$1.53bn$1.14bn$1.14bn$1.14bn$1.13bn$806.3m—$200,000$700,000$17.0m
Shareholders' equity−$99.3m−$139.6m$158.7m$60.2m$645.0m$1.30bn$798.4m$483.2m$308.6m$79.7m
Shares outstanding129m124m119m103m102m100m94m84m71m13m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$184.8m−$239.9m−$325.0m−$309.5m−$209.0m−$103.9m−$47.1m−$72.2m−$72.2m−$36.7m
Capital spending−$48.3m−$35.1m−$20.5m−$77.5m−$75.0m−$54.1m−$21.3m−$20.2m−$9.0m−$1.8m
Free cash flow−$233.1m−$274.9m−$345.5m−$386.9m−$284.1m−$158.0m−$68.4m−$92.4m−$81.2m−$38.5m
Dividends paid————−$17.9m−$7.1m—−$3.2m——

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$335.0m$301.7m$281.3m$265.2m$232.1m$203.5m$201.8m$191.5m
Operating income−$129.1m−$121.3m−$120.8m−$99.0m−$106.4m−$111.0m−$126.0m−$117.3m
Net income−$120.1m−$112.1m−$128.5m−$92.7m−$99.9m−$95.2m−$111.0m−$107.8m
Diluted earnings per share-0.91-0.85-1.00-0.72-0.78-0.74-0.90-0.87
Cash from operations−$57.0m−$65.0m−$26.0m−$35.0m−$60.0m−$62.0m−$64.0m−$51.0m
Capital spending−$11.0m−$5.0m−$27.0m−$10.0m−$5.0m−$4.0m−$18.0m−$4.0m
Free cash flow−$68.0m−$70.0m−$53.0m−$45.0m−$65.0m−$66.0m−$82.0m−$55.0m
Total assets$1.91bn$1.92bn$2.01bn$1.28bn$1.33bn$1.34bn$1.49bn$1.54bn
Cash and short-term investments$1.05bn$1.10bn$1.20bn$580.0m$629.1m$698.6m$840.0m$999.1m
Debt$1.53bn$1.53bn$1.53bn$1.14bn$1.14bn$1.15bn$1.17bn$1.17bn
Shareholders' equity−$222.9m−$181.1m−$99.3m−$354.5m−$305.5m−$250.8m−$139.6m−$60.1m

Financial ratios

Data as of 1 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-44.5%-60.0%-100.1%-121.1%-110.0%-88.9%
Net margin-42.4%-59.0%-85.0%-145.6%-108.6%-88.5%
Return on equity419.2%312.5%-302.1%-1087.7%-62.9%-19.5%
Return on assets-20.7%-29.4%-26.8%-40.7%-18.4%-11.2%
Free cash flow yield-0.6%-0.9%-1.4%-1.3%-0.7%-0.3%
Revenue growth32.9%31.0%25.5%20.3%30.3%33.8%
Earnings growth-4.6%-9.0%-26.8%61.4%59.8%235.5%
Current ratio4.84x4.68x6.54x6.17x5.72x28.27x
Debt to equity-15.42x-8.39x7.36x19.26x1.78x0.63x
Equity ratio-4.9%-9.4%8.9%3.7%29.3%57.2%
Interest coverage-112.20x-171.87x-219.06x-211.24x-159.49x-53.49x
R&D as a share of sales37.1%47.1%65.1%83.2%70.4%52.3%
Buybacks as a share of market value-4.0%-4.4%-15.6%-0.8%-1.7%-6.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue29.8%28.2%—
Operating income-7.0%11.4%—
Net income-14.0%10.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-31.6-8.7-6.7-4.3-25.1-50.8-97.1-37.2
Price to sales13.45.15.76.227.445.734.535.4

Market value over time

31 Oct 2018 to 30 Sept 2026, in USD

$435.2m$23.56bn

Share price return

Finished calendar years

20252024202320222021202020192018
Return200%16%-8%-70%-23%57%132%11%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.